The Technical Document on Minimum Required Performance Levels for Detection and Identification of Non-Threshold Substances has undergone a revision by WADA’s Laboratory Expert Group (LabEG).

The new version of the document, TD2018MRPL, includes the following main modifications:

1.0 Minimum Required Performance Levels (MRPL)

Table 1 was modified to reflect the changes in the 2018 Prohibited List.

1) The section **S1.1b Endogenous AAS Administered Exogenously** was added, with the following specific examples:
   - 19-norandrosterone (19-NA) and 19-noretiocholanolone (19-NE): 2 ng/mL
   - Boldenone: 5 ng/mL

2) **S2.2. HIF Stabilizers** was changed to **S2.1.2. HIF Activating Agents**

3) **S2.3 Gonadotropin Releasing Hormone (GnRH)** was changed to **S2.2.1 Gonadotropin (CG/LH) Releasing Factors**

4) A new subsection was created in **S2.2.3 Growth Hormone (GH), its fragments and Releasing Factors:**
   - GH fragments: AOD9604, hGH 176-191: 2 ng/mL

4) A new section was created to include **S2.3 Growth Factors and Growth Factor Modulators:** TB-500 (N-Ac-LKKTETQ): 2 ng/mL

- Footnotes have been reorganized to follow the chronological order of appearance in the text.
- A new footnote (b) has been added to clarify the detection and reporting of 19-norsteroids.
- A new footnote (c) has been added to detail the conditions of reporting an Adverse Analytical Finding for boldenone between 5 and 30 ng/mL.
- Footnote (d) was removed as glycerol is not considered as a Prohibited Substance anymore according to the List 2018.
• In footnote (e) it is specified that when salbutamol or formoterol are detected in conjunction with a prohibited diuretic or masking agent, these substances shall be reported as an Adverse Analytical Finding at any concentration.

• In footnote (d) (previously footnote (i)), a sentence has been added to clarify that Laboratories shall apply the analysis of gonadotropin-releasing factors as a Confirmation Procedure for elevated total LH findings.

4.0 Reporting of Non-Threshold Substances

• Footnote 8 has been modified to further clarify the application of reporting limits for substances in classes S6, S7, S8, S9 and P1, in particular when the analytical method includes the determination of phase-II Metabolites.

• Footnote 10 has been added to specify that the reporting limit for octapamine applies to the sum of the parent compound and its phase–II sulfate Metabolite.